MedTrace Logo

The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

NCT02905916 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2016-09-19

No results posted yet for this study

Summary

The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.

Conditions

  • Mammary Cancer
  • Lymphoma
  • Bone Tumour
  • Gynecological Tumors

Interventions

DRUG

PEG-rhG-CSF

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Jun Zhu, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02905916 on ClinicalTrials.gov